{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:18:56Z","timestamp":1761175136189,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ijid.2021.04.032","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T06:12:28Z","timestamp":1618467148000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-8223","authenticated-orcid":false,"given":"Jorge","family":"Andrade-Sierra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2062-5262","authenticated-orcid":false,"given":"Alejandro","family":"Heredia-Pimentel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6868-6465","authenticated-orcid":false,"given":"Enrique","family":"Rojas-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-3056","authenticated-orcid":false,"given":"Diana","family":"Ram\u00edrez Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 I.","family":"Cerrillos-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra G.","family":"Miranda-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Evangelista-Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-7632","authenticated-orcid":false,"given":"Petra","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basilio","family":"Jalomo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Gonzalez-Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"G\u00f3mez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Medina-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Nieves-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.04.032_bib0005","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfm873","article-title":"CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A","volume":"23","author":"Abou-Ayache","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.transproceed.2015.12.013","article-title":"Early steroid withdrawal in recipients of a kidney transplant from a living donor: experience of a single Mexican center","volume":"48","author":"Andrade-Sierra","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0015","first-page":"216","article-title":"Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab","volume":"34","author":"Andrade-Sierra","year":"2014","journal-title":"Nefrologia"},{"key":"10.1016\/j.ijid.2021.04.032_bib0020","first-page":"1234A","article-title":"Low dose mycophenolate mofetil in kidney transplant recipients and its association with infections diseases and acute rejection","volume":"29","author":"Andrade-Sierra","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijid.2021.04.032_bib0025","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/j.1600-6143.2010.03114.x","article-title":"Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients","volume":"10","author":"Asberg","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1399-3062.2010.00533.x","article-title":"Cytomegalovirus risk factors in renal transplantation with modern immunosuppression","volume":"12","author":"Bataille","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1399-3062.2011.00624.x","article-title":"Risk factors for late-onset cytomegalovirus disease in donor seropositive\/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis","volume":"13","author":"Boudreault","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0040","article-title":"Among CMV-positive renal transplant patients receiving non-T-cell depleting induction, the absence of CMV disease prevention is a safe strategy: a retrospective cohort of 372 patients","author":"Boulay","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0045","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00007890-199712270-00036","article-title":"Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients","volume":"64","author":"Brennan","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0050","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1016\/j.transproceed.2015.08.011","article-title":"Risk Factors of cytomegalovirus disease in kidney transplant recipients: a Single-Center Study in Thailand","volume":"47","author":"Chiasakul","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0055","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.transproceed.2011.11.053","article-title":"Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors","volume":"44","author":"Cordero","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0060","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.transproceed.2009.05.008","article-title":"Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients","volume":"41","author":"Corona-Nakamura","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0065","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jit064","article-title":"Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients","volume":"207","author":"Courivaud","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0070","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.ajkd.2011.04.010","article-title":"Human cytomegalovirus and kidney transplantation: a clinician\u2019s update","volume":"58","author":"De Keyzer","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3947\/ic.2017.49.4.255","article-title":"Cytomegalovirus infection after renal transplantation: occurrence, clinical features, and the cutoff for Antigenemia in a University Hospital in Brazil","volume":"49","author":"de Matos","year":"2017","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijid.2021.04.032_bib0080","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.transproceed.2013.07.070","article-title":"Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients","volume":"46","author":"Diaz","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0085","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13106","article-title":"Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy","volume":"21","author":"Felipe","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0090","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/tri.12586","article-title":"Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice","volume":"28","author":"Fernandez-Ruiz","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.ijid.2021.04.032_bib0095","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/01.TP.0000142619.01510.A5","article-title":"Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients","volume":"78","author":"Freeman","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0100","doi-asserted-by":"crossref","DOI":"10.5812\/numonthly.31635","article-title":"Human leukocyte antigen alleles and cytomegalovirus infection after renal transplantation","volume":"7","author":"Futohi","year":"2015","journal-title":"Nephrourol Mon"},{"key":"10.1016\/j.ijid.2021.04.032_bib0105","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13189","article-title":"The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients","volume":"21","author":"Gardiner","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.idc.2010.02.003","article-title":"Viral impact on long-term kidney graft function","volume":"24","author":"Helantera","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijid.2021.04.032_bib0120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/tid.12247","article-title":"Current characteristics and outcome of cytomegalovirus infections after kidney transplantation","volume":"16","author":"Helantera","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0125","first-page":"1","article-title":"Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention","author":"Hellemans","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0130","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10096-019-03744-3","article-title":"Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient","volume":"39","author":"Hemmersbach-Miller","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0135","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.bjid.2016.08.007","article-title":"Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation","volume":"20","author":"Henrique Pinto","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0140","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003774.pub4","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2021.04.032_bib0145","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0150","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/ajt.13781","article-title":"Easier control of late-onset cytomegalovirus disease following universal prophylaxis through an early antiviral immune response in donor-positive, recipient-negative kidney transplants","volume":"16","author":"Kaminski","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16132","article-title":"CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept","volume":"21","author":"Karadkhele","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0160","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.idc.2018.04.008","article-title":"Prevention and treatment of cytomegalovirus infections in solid organ transplant recipients","volume":"32","author":"Koval","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijid.2021.04.032_bib0170","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.transproceed.2011.12.025","article-title":"Post-renal transplant cytomegalovirus infection: study of risk factors","volume":"44","author":"Kute","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0175","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/tid.12227","article-title":"Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients","volume":"16","author":"Lee","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0180","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2021.04.032_bib0185","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2012.04.036","article-title":"Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+\/R- kidney transplant patients receiving thymoglobulin induction","volume":"45","author":"Luan","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0190","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/TP.0b013e318200000c","article-title":"Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients","volume":"91","author":"Luan","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0195","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1399-3062.2010.00532.x","article-title":"Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients","volume":"12","author":"Luan","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0200","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/tri.12318","article-title":"Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm","volume":"27","author":"Lucia","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.ijid.2021.04.032_bib0205","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/ajt.12388","article-title":"Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients","volume":"13","author":"Manuel","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0210","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/tid.12226","article-title":"Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+\/R-): experience from the RESITRA-REIPI cohort","volume":"16","author":"Meije","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0215","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1111\/ajt.13396","article-title":"Primary cytomegalovirus infection significantly impacts circulating T cells in kidney transplant recipients","volume":"15","author":"Meijers","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0220","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.transproceed.2020.02.162","article-title":"Cytomegalovirus infection in postrenal transplant recipients: 18 years\u2019 experience from a tertiary referral center","volume":"52","author":"Minz","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0225","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0230","first-page":"231","article-title":"Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients","volume":"8","author":"Nafar","year":"2014","journal-title":"Iran J Kidney Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0235","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/TP.0000000000001338","article-title":"Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients","volume":"101","author":"Natori","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0240","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0245","first-page":"606A","article-title":"Basiiximab versus Lowdoses of thymoglobulin as induction therapies in kidney transplant recipients","volume":"24","author":"Perez-Vega","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijid.2021.04.032_bib0250","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.transproceed.2017.02.019","article-title":"Pre-emptive therapy for the treatment of cytomegalovirus after kidney transplantation","volume":"49","author":"Pretagostini","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0255","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/ctr.12810","article-title":"Cytomegalovirus infection in high-risk kidney transplant recipients receiving thymoglobulin induction-a single-center experience","volume":"30","author":"Puttarajappa","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0260","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1600-6143.2003.00647.x","article-title":"Cellular immune responses to cytomegalovirus in renal transplant recipients","volume":"5","author":"Radha","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0265","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13577","article-title":"The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis","author":"Raiha","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0270","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.2174\/1381612826666200531152901","article-title":"Cytomegalovirus in solid organ transplant recipients: clinical updates, challenges and future directions","volume":"26","author":"Razonable","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ijid.2021.04.032_bib0275","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1086\/324516","article-title":"Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir","volume":"184","author":"Razonable","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0280","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12929","article-title":"Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: outcome and risk factors for late CMV disease","volume":"20","author":"Reusing","year":"2018","journal-title":"Transpl Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.ijid.2021.04.032_bib0285","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/ndt\/gfh1079","article-title":"Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation","volume":"20","author":"Ricart","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0290","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1086\/591532","article-title":"Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation","volume":"47","author":"San Juan","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.transproceed.2014.11.018","article-title":"Safety and efficacy of induction treatment with low thymoglobulin doses in kidney transplantation from expanded-criteria donors","volume":"47","author":"Sancho Calabuig","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2021.04.032_bib0300","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/TP.0000000000000030","article-title":"Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation","volume":"98","author":"Santos","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0305","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12879-017-2599-y","article-title":"Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience","volume":"17","author":"Selvey","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0310","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","article-title":"Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment","volume":"98","author":"Stern","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0315","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0320","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/ndt\/15.5.711","article-title":"The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation","volume":"15","author":"ter Meulen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijid.2021.04.032_bib0325","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trre.2016.04.001","article-title":"Management of cytomegalovirus infection in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations","volume":"30","author":"Torre-Cisneros","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.ijid.2021.04.032_bib0330","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.tp.0000229390.01369.4a","article-title":"Tacrolimus\/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine\/azathioprine","volume":"82","author":"Vacher-Coponat","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2021.04.032_bib0335","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/tid.12408","article-title":"Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome","volume":"17","author":"Viot","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.032_bib0340","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007746.pub2","article-title":"Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients","author":"Wagner","year":"2015","journal-title":"Cochrane Database Syst Rev"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221003428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221003428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:56:30Z","timestamp":1761119790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221003428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":68,"alternative-id":["S1201971221003428"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.04.032","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}